You will automatically be redirected in 10 seconds. Or, you can click the link below:

https://www.streetinsider.com/PRNewswire/Medivir%C2%B4s+licensee%2C+Tango+Therapeutics%2C+has+dosed+the+first+patient+with+TNG348%2C+a+novel+USP1+inhibitor%2C+in+a+phase+12+clinical+study/22591879.html